BeiGene, Ltd. (BGNE)
After hours:
| Previous Close | 191.58 |
| Open | 192.81 |
| Bid | 191.03 x 100 |
| Ask | 191.46 x 100 |
| Day's Range | 188.51 - 193.04 |
| 52 Week Range | 126.97 - 213.83 |
| Volume | |
| Avg. Volume | 269,400 |
| Market Cap | 21.018B |
| Beta (5Y Monthly) | 0.61 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.94 |
| Earnings Date | Nov 07, 2024 - Nov 14, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 273.43 |
ZacksWall Street Analysts See a 27.84% Upside in BeiGene (BGNE): Can the Stock Really Move This High?
The consensus price target hints at a 27.8% upside potential for BeiGene (BGNE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Simply Wall St.3 US Stocks That Could Be Trading At A Discount
As the major U.S. stock indexes edged higher recently, investors are keeping a close eye on significant earnings reports and economic indicators that could influence market sentiment. Amid this cautious optimism, identifying undervalued stocks can be crucial for those looking to capitalize on potential discounts in the current market landscape.
Business WireBeiGene to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
SAN MATEO, Calif., August 28, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024, with a fireside chat at 10 a.m. EDT.
